{'fraction_non_alphanumeric': 0.028350515463917526, 'fraction_numerical': 0.014175257731958763, 'mean_word_length': 5.584745762711864, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The antidepressant viloxazin. A multicenter study under practice conditions].

As part of an open multicentre study involving 22 psychiatric clinics 212 patients with depressive symptoms (predominantly endogenous depression) were treated over one month with viloxazine. The drug was administered either alone or- if it seemed clinically necessary--in combination with minor or major tranquilizers. Overall, the depressive symptoms improved in 77% of the cases (10-20% total remissions) of both endogenous and reactive depression. Depressive mood, anxiety and reduced activity were the symptoms which responded best to therapy. In sleep disturbances, psychomotor and internal unrest combination therapy with minor or major tranquilizers was superior to viloxazine given alone.